OGEN — ORAGENICS INC

—
NYSE · Health Care · Pharmaceuticals · CIK 1174940 ·
Last close
$0.21
Market Cap
$947.5K
52W High
$1.11
52W Low
$0.17
ADV30
1,745,743
Next earnings
—
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — — — —
Mar 2026 0 — -2,255,927 -2,201,243 7,489,636 6,107,078 1,307,878
Dec 2025 0 — -2,498,301 -2,286,870 10,067,764 4,399,726 1,786,359
Sep 2025 0 — -3,123,773 -3,066,589 12,705,544 11,403,766 2,874,108

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-9,334,941
Investing CF
$4,000,000
Financing CF
$12,020,941
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.14
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-228,829,902
Inventory
—
Receivables
$0
ST Investments
$0
EBIT TTM
$-9,395,742
Pretax Income TTM
$-9,986,272
Interest Exp TTM
$590,530
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -9,362,503 -9,842,487 10,067,764 1,786,359 8,281,405 -9,246,387
Dec 2024 0 -10,558,815 -10,567,918 1,472,510 1,684,395 -211,885 -8,597,382
Dec 2023 0 -20,904,903 -20,655,737 4,966,335 1,798,181 3,168,154 -7,290,880
Dec 2022 0 -14,420,768 -14,288,389 14,758,025 1,748,723 13,009,302 -15,228,483
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$226,135
NetIncome TTM
$-10,083,409
OpCashFlow TTM
—
Assets (Latest)
$5,492,501
Forward EPS
$-10.80

Peers — same industry

TickerNameMarket CapLastDaily %
SKVI SKINVISIBLE, INC. $972.7K $0.18 —
ATXI AVENUE THERAPEUTICS, INC. $922.6K $0.28 —
APVO Aptevo Therapeutics Inc. $834.5K $0.46 —
GOVX GeoVax Labs, Inc. $1.09M $2.01 —
PTIX Protagenic Therapeutics, Inc.\new $814.6K $0.45 —

News headlines (Yahoo Finance, 1h cache)

Oragenics: Q3 Earnings Snapshot
2026-11-12 22:19 · Yahoo
Oragenics Receives NYSE American Approval of Compliance Plan and Extension Through February 2028
2026-11-12 21:00 · Yahoo
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
2026-09-16 12:30 · Yahoo
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
2026-08-28 20:25 · Yahoo
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
2026-07-07 12:30 · Yahoo
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
2026-05-07 12:30 · Yahoo
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
2026-04-13 12:30 · Yahoo
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
2026-05-05 12:30 · Yahoo
ORAGENICS PROVIDES INVESTOR UPDATE
2026-05-18 12:30 · Yahoo
Sidoti Events, LLC's May Micro-Cap Virtual Conference
2026-05-20 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.